Drug Search Results
Using advanced filters...
Advanced Search [+]

Tafamidis

Alternative Names: tafamidis, fx-005, fx005, fx 005, vyndaqel, tafamidis meglumine, vyndamax, Fx-1006A, Fx1006A, Fx 1006A
Latest Update: 2025-03-31
Latest Update Note: News Article

Product Description

Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK574508/)

Mechanisms of Action: TTR Stabilizer

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tafamidis

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Hong Kong, Italy, Japan, Netherlands, Spain, Sweden, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Cardiomyopathies|Transthyretin Amyloidosis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B3461115

P1

Recruiting

Healthy Volunteers

2025-03-06

B3461114

P1

Completed

Healthy Volunteers

2024-05-27

ATTR-CM

P3

Completed

Transthyretin Amyloidosis|Cardiomyopathies

2023-10-26

2016-000868-42

P3

Active, not recruiting

Transthyretin Amyloidosis

2021-07-26

Recent News Events